Heterogeneity | ||||||||
---|---|---|---|---|---|---|---|---|

Outcome or subgroup | Number of studies | Number of participants | Summary estimate and model | Effect estimate (95% CI) with p values where significant | χ^{2} | d.f. | p Value | I^{2} (%) |

Exercise capacity | ||||||||

≤12-month follow-up | 19 | 1876 | Standard mean difference, random-effects model | −0.10 (−0.29 to 0.08) | 63.30 | 18 | <0.00001 | 72 |

12–24-month follow-up | 3 | 1074 | Standard mean difference, fixed-effects model | 0.11 (−0.01 to 0.23) | 0.97 | 2 | 0.62 | 0 |

Blood pressure (mm Hg) at 3–12-month follow-up | ||||||||

Systolic | 9 | 1117 | Mean difference, random-effects model | 0.19 (−3.37 to 3.75) | 23.07 | 8 | 0.003 | 65 |

Diastolic | 8 | 991 | Mean difference, fixed-effects model | −1.86 (−2.95 to −0.76) lower in centre-based group (p=0.009) | 11.12 | 7 | 0.13 | 37 |

Cholesterol (mmol/L) at 3–12-month follow-up | ||||||||

Total | 9 | 1109 | Mean difference, random-effects model | −0.07 (−0.24 to 0.11) | 20.98 | 8 | 0.007 | 62 |

HDL | 7 | 883 | Mean difference, fixed-effects model | −0.07 (−0.11 to −0.03) lower in centre-based group (p=0.001) | 10.49 | 6 | 0.11 | 43 |

LDL | 5 | 388 | Mean difference, random-effects model | −0.06 (−0.27 to 0.15) | 10.60 | 4 | 0.03 | 62 |

Triglycerides | 5 | 354 | Mean difference, random-effects model | −0.16 (−0.38 to 0.07) | 7.59 | 4 | 0.11 | 47 |

Smoking (3–12 months) | 6 | 986 | Relative risk, fixed-effects model | 0.98 (0.79 to 1.21) | 4.48 | 5 | 0.48 | 0 |

Completers | 18 | 1984 | Risk ratio, fixed-effects model | 1.04 (1.01 to 1.07) higher completion in home-based group (p=0.009) | 30.26 | 17 | 0.02 | 44 |

Mortality | 7 | 1166 | Relative risk, fixed-effects model | 0.79 (0.43 to 1.47) | 1.60 | 5 | 0.90 | 0 |

HDL, high-density lipoprotein; LDL, low-density lipoprotein.